[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609769":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":188,"collaborators":19,"id":190,"slug":191,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":192,"sex":198,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":19,"studyType":204,"phases":205,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},{"fullName":5,"class":6},"Alexion Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ALXN2350","EXPERIMENTAL","Participants will receive one of three dose levels of ALXN2350 depending on the cohort.",[13],"Drug: ALXN2350",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene. It is administered as a single intravenous (IV) infusion.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Alexion Pharmaceuticals, Inc. (Sponsor)","CONTACT","1-855-752-2356","clinicaltrials@alexion.com",[27,46,60,74,88,102,116,129,144,160,173],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Research Site","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-86.80249,33.52066,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":19,"email":45},"Nehal Vekariya","205-934-7173","nvekariya@uabmc.edu",{"facility":28,"status":29,"city":47,"state":48,"zip":49,"country":33,"countryCode":34,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Palo Alto","California","94304",{"type":36,"coordinates":51},[52,53],-122.14302,37.44188,{"lat":53,"lon":52},[56],{"name":57,"role":23,"phone":58,"phoneExt":19,"email":59},"Ashna Deo","650-497-7360","adrost@stanford.edu",{"facility":28,"status":29,"city":61,"state":62,"zip":63,"country":33,"countryCode":34,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Boston","Massachusetts","02115",{"type":36,"coordinates":65},[66,67],-71.05977,42.35843,{"lat":67,"lon":66},[70],{"name":71,"role":23,"phone":72,"phoneExt":19,"email":73},"Alyx Vogle","617-732-6320","avogle@bwh.harvard.edu",{"facility":28,"status":29,"city":75,"state":76,"zip":77,"country":33,"countryCode":34,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Cincinnati","Ohio","45219",{"type":36,"coordinates":79},[80,81],-84.51439,39.12711,{"lat":81,"lon":80},[84],{"name":85,"role":23,"phone":86,"phoneExt":19,"email":87},"Michael Weber","513-585-1777","michael.weber@thechristhospital.com",{"facility":28,"status":29,"city":89,"state":90,"zip":91,"country":33,"countryCode":34,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Portland","Oregon","97239-3098",{"type":36,"coordinates":93},[94,95],-122.67621,45.52345,{"lat":95,"lon":94},[98],{"name":99,"role":23,"phone":100,"phoneExt":19,"email":101},"Hailey Volk","503-418-2246","volkh@ohsu.edu",{"facility":28,"status":29,"city":103,"state":104,"zip":105,"country":33,"countryCode":34,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Philadelphia","Pennsylvania","19104",{"type":36,"coordinates":107},[108,109],-75.16362,39.95238,{"lat":109,"lon":108},[112],{"name":113,"role":23,"phone":114,"phoneExt":19,"email":115},"Joseph Puhl","267-399-3049","joseph.puhl@pennmedicine.upenn.edu",{"facility":28,"status":29,"city":117,"state":118,"zip":119,"country":33,"countryCode":34,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Houston","Texas","77030",{"type":36,"coordinates":121},[122,123],-95.36327,29.76328,{"lat":123,"lon":122},[126],{"name":127,"role":23,"phone":128,"phoneExt":19,"email":19},"Jennifer Garrett","346-238-4516",{"facility":28,"status":29,"city":130,"state":19,"zip":131,"country":132,"countryCode":133,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Massa","54100","Italy","IT",{"type":36,"coordinates":135},[136,137],10.13927,44.03541,{"lat":137,"lon":136},[140],{"name":141,"role":23,"phone":142,"phoneExt":19,"email":143},"Claudio Passino","+39 0503152191","passino@ftgm.it",{"facility":28,"status":29,"city":145,"state":19,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Barcelona","08035","Spain","ES",{"type":36,"coordinates":150},[151,152],2.15899,41.38879,{"lat":152,"lon":151},[155],{"name":156,"role":23,"phone":157,"phoneExt":158,"email":159},"Germán Escudero","+34 934896329","6267","german.escudero@vhir.org",{"facility":28,"status":29,"city":161,"state":19,"zip":162,"country":147,"countryCode":148,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Majadahonda","28222",{"type":36,"coordinates":164},[165,166],-3.87182,40.47353,{"lat":166,"lon":165},[169],{"name":170,"role":23,"phone":171,"phoneExt":19,"email":172},"María de la Iglesia","+34 91 191 67 49","cardiopatiasfamiliares.hpth@salud.madrid.org",{"facility":28,"status":29,"city":174,"state":19,"zip":175,"country":176,"countryCode":177,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"London","SW3 6NP","United Kingdom","UK",{"type":36,"coordinates":179},[180,181],-0.12574,51.50853,{"lat":181,"lon":180},[184],{"name":185,"role":23,"phone":186,"phoneExt":19,"email":187},"Nikula Vicario","+44 0330 128 4043","Nikula.vicario@nhs.net",{"type":189,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100609769","phase-1-alxn2350-in-adult-participants-with-bag3-associated-dilated-cardiomyopathy-100609769",false,"NCT07218887","ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy","A Phase 1\u002F2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy","DCMRestore","Inclusion Criteria:\n\n* Pathogenic or likely pathogenic mutation in BAG3\n* Medical history of diagnosis of DCM\n* Stable combination of HF SoC medications\n* Adequate acoustic windows for echocardiography\n* LVEF \\> 15% and ≤ 45% at Screening by echocardiography\n* Diagnosis of chronic HF for at least 3 months\n* NYHA Class I\u002FII\u002FIII at Screening\n\nExclusion Criteria:\n\n* Presence of antibodies to AAV9\n* Presence of a pathogenic or likely pathogenic variant in another gene where that other gene is authoritatively recognized as causal for DCM\n* Decompensated HF\n* Cardiac ventricular arrhythmia that requires treatment\n* History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency\n* NYHA Class IV\n* History of substance abuse that could contribute to cardiac dysfunction\n\nNote: Other inclusion and exclusion criteria may apply.","ALL","18 Years","70 Years",{"count":202,"type":203},6,"ESTIMATED","INTERVENTIONAL",[206,207],"PHASE1","PHASE2","This Phase 1\u002F2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.",[210],"BAG3 Mutation Associated Dilated Cardiomyopathy",[9,212,210],"Gene Therapy","2026-08-18",{"date":215,"type":216},"2026-08-19","ACTUAL",{"date":218,"type":216},"2025-10-24",{"date":220,"type":203},"2032-01-27",{"name":5,"class":6},11]